ALDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aldeyra Therapeutics Inc (ALDX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has faced significant negative catalysts, including a sharp price decline due to an FDA rejection, poor financial performance, and ongoing legal investigations. Additionally, technical indicators and analyst ratings do not support a bullish outlook. It is advisable to hold off on investing in this stock at this time.
The technical indicators for ALDX are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 29.384, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.284), but there is no indication of a reversal or upward momentum.
Some insider buying activity was noted, with Richard Douglas purchasing 70,000 shares, which could indicate confidence in the stock.
The FDA issued a complete response letter rejecting Aldeyra's drug reproxalap, leading to a 70.7% stock price drop. Rosen Law Firm has initiated investigations and a class action lawsuit against the company for alleged misleading business practices. Analyst Matthew Caufield downgraded the stock to Neutral from Buy, with a significant price target reduction from $10 to $2.
The company's Q4 2025 financials show no revenue growth (0% YoY), a significant net income drop (-59.13% YoY), and a decline in EPS (-59.26% YoY). Gross margin remains at 0%. Overall, the financial performance is poor.
Analyst Matthew Caufield downgraded the stock to Neutral from Buy, reducing the price target from $10 to $2 due to the FDA rejection and reduced probability of success for reproxalap from 75% to 40%.
